Retina

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The partnership was announced in August of this year.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.